Health care was the top performing sector by far in November, with the S & P 500 Health Care Sector gaining an impressive 9.1%. The rally appears to be the start of a cyclical uptrend, lending a bullish outlook for 2026. While some health care stocks are overstretched in the short term, we have noticed actionable technical catalysts in medical device stocks. There are recent breakouts to new highs like IDEXX Laboratories (IDXX) and STERIS PLC (STE) , and compelling turnaround opportunities in names like GE Healthcare Technologies Inc. (GEHC) and Medtronic PLC (MDT) . To track a basket of medical device stocks, the iShares U.S. Medical Devices ETF (IHI) is a popular choice. The long-term trend for IHI is neutral, noting that resistance from the 2021 high remains in place. The four-year trading range has not reversed the secular uptrend because price remains above the monthly cloud model. There is technical evidence on the monthly chart that bodes well for a trading-range breakout. IHI has formed a bullish cup-and-handle pattern and has new upturns in its monthly MACD and stochastic oscillator. Should a breakout become decisive, it would affirm a bullish outlook for 2026, targeting a measured-move projection of about $80. The weekly chart of IHI shows that an uptrend has taken hold, now above the weekly cloud model, which is long-term support near $59. The upper boundary of the cloud is rising looking out into Q2 2026 for a bullish long-term takeaway. IHI has a fresh breakout above resistance near $63, which goes back to May. The breakout reverses a six-month trading range to the upside in a bullish intermediate-term development. The breakout is associated with positive short- and intermediate-term momentum per the daily and weekly MACDs, as well as a bullish shift in relative momentum. Over the next several days, we would like to see IHI hold above the breakout point near $63, which is now initial support. The ratio of IHI to the S & P 500 Index (SPX) is above its 50-day MA, which has turned higher, indicating that the trend has shifted positive for the next several weeks. The long-term trend of IHI vs. SPX is lower, but there are long-term signs of downside exhaustion suggesting medical device stocks will see several months of improved performance relative to the broader market. Overall, there is evidence across timeframes to suggest IHI can reach new all-time highs, supporting a strong 2026 for medical devices stocks and the broader healthcare sector. —Katie Stockton with Will Tamplin Access research from Fairlead Strategies for free here . DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer. Fairlead Strategies Disclaimer: This communication has been prepared by Fairlead Strategies LLC (“Fairlead Strategies”) for informational purposes only. This material is for illustration and discussion purposes and not intended to be, nor construed as, financial, legal, tax or investment advice. You should consult appropriate advisors concerning such matters. This material presents information through the date indicated, reflecting the author’s current expectations, and is subject to revision by the author, though the author is under no obligation to do so. This material may contain commentary on broad-based indices, market conditions, different types of securities, and cryptocurrencies, using the discipline of technical analysis, which evaluates the demand and supply based on market pricing. The views expressed herein are solely those of the author. This material should not be construed as a recommendation, or advice or an offer or solicitation with respect to the purchase or sale of any investment. The information is not intended to provide a basis on which you could make an investment decision on any particular security or its issuer. This document is intended for CNBC Pro subscribers only and is not for distribution to the general public. Certain information has been provided by and/or is based on third party sources and, although such information is believed to be reliable, no representation is made with respect to the accuracy, completeness, or timeliness of such information. This information may be subject to change without notice. Fairlead Strategies undertakes no obligation to maintain or update this material based on subsequent information and events or to provide you with any additional or supplemental information or any update to or correction of the information contained herein. Fairlead Strategies, its officers, employees, affiliates and partners shall not be liable to any person in any way whatsoever for any losses, costs, or claims for your reliance on this material. Nothing herein is, or shall be relied on as, a promise or representation as to future performance. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Opinions expressed in this material may differ or be contrary to opinions expressed, or actions taken, by Fairlead Strategies or its affiliates, or their respective officers, directors, or employees. In addition, any opinions and assumptions expressed herein are made as of the date of this communication and are subject to change and/or withdrawal without notice. Fairlead Strategies or its affiliates may have positions in financial instruments mentioned, may have acquired such positions at prices no longer available, and may have interests different from or adverse to your interests or inconsistent with the advice herein. Any investments made are made under the same terms as nonaffiliated investors and do not constitute a controlling interest. No liability is accepted by Fairlead Strategies, its officers, employees, affiliates, or partners for any losses that may arise from any use of the information contained herein. Any financial instruments mentioned herein are speculative in nature and may involve risk to principal and interest. Any prices or levels shown are either historical or purely indicative. This material does not take into account the particular investment objectives or financial circumstances, objectives or needs of any specific investor, and are not intended as recommendations of particular securities, investment products, or other financial products or strategies to particular clients. Securities, investment products, other financial products or strategies discussed herein may not be suitable for all investors. The recipient of this information must make its own independent decisions regarding any securities, investment products or other financial products mentioned herein. The material should not be provided to any person in a jurisdiction where its provision or use would be contrary to local laws, rules, or regulations. This material is not to be reproduced or redistributed absent the written consent of Fairlead Strategies.
